Solu Therapeutics Closes $41M Series A…

SALT LAKE CITY--(December 19, 2024)--Sorriso Pharmaceuticals, a biopharmaceutical company developing novel orally dosed antibodies for immune-mediated disease, today announced positive results from its Phase 1b clinical trial evaluating SOR102, an oral, dual-acting biologic targeting TNFα and IL-23, in patients with ulcerative colitis (UC). The study met its primary objectives, demonstrating a favorable safety and tolerability profile. Additionally, key exploratory efficacy endpoints showed promising activity of SOR102 across multiple clinical endpoints. This is the first successful demonstration of an orally dosed antibody delivering clinical efficacy.

SALT LAKE CITY, UT, UNITED STATES, September 3, 2024 -- Sorriso Pharmaceuticals, a biopharmaceutical company developing novel oral antibodies for immune-mediated disease, today announced the completion of patient enrollment in its Phase 1b clinical trial evaluating the safety, tolerability, and preliminary efficacy of SOR102, a bispecific oral dual-acting biologic for the treatment of ulcerative colitis.